All In Biotech

Drug Trial Radar · NCT07940946

A Phase 3, Multicenter Study of Vorasidenib in Combination With Temozolomide (TMZ) in Participants With IDH1- or IDH2 Mutant High-grade Astrocytoma.

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Vorasidenib in Combination With Temozolomide (TMZ) in Participants With Newly Diagnosed IDH1- or IDH2-mutant High-grade Astrocytoma (CNS WHO Grade 3 or 4).

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 550 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

550

Planned (sponsor's estimate)

Start

Mar 1, 2027

Primary completion

Nov 1, 2034

Study completion Nov 1, 2034

Sponsor

Lead sponsor
Institut de Recherches Internationales ServierAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to establish the efficacy and safety of vorasidenib in combination with TMZ, compared to placebo with TMZ, in participants ages 12 and older with newly diagnosed, isocitrate dehydrogenase (IDH) mutant high-grade astrocytoma. The study will include a screening period, a treatment period consisting of continuous 28-day cycles of treatment, a safety follow-up, progression free survival follow-up, and survival follow-ups every 3 months until study completion. During Cycles 1 through 12 of the treatment period participants will receive TMZ along with either vorasidenib or placebo and then from Cycle 13 through the end of treatment participants will only receive vorasidenib or placebo. At study visits participants may undergo blood tests, magnetic resonance imaging (MRI), electrocardiogram (ECG), vital sign checks, questionnaires, and physical exams.

Conditions

  • IDH-mutant High-grade Astrocytoma

Interventions

  • VorasidenibDrug

    Tablets to be taken by mouth, once daily, until study participation stops

  • PlaceboDrug

    Tablets to be taken by mouth, once daily, until study participation stops

  • Temozolomide (TMZ)Drug

    Tablets or capsules (depending on the form available in the participants country) to be taken by mouth, once daily on days 1-5 of each cycle, from Cycle 1 through Cycle 12. Cycles are 28-days each.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Through study completion, approximately 7.5 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.